Triumvera, co-founded by McMaster's professor Jonathan Bramson, looks to progress its solid tumour therapeutic candidate.
Triumvira Immunologics, a US-based cancer therapeutics developer co-founded by McMaster University faculty, expanded its series A round to $100m yesterday.
The $45m extension featured Leaps by Bayer, the impact corporate venturing arm of pharmaceutical and chemicals group Bayer, Multiple Myeloma Research Foundation’s venture philanthropy subsidiary, B Capital Group, Atem Capital, Myeloma Investment Fund, Northpond Ventures and undisclosed other investors.
Triumvira is working on non-gene edited autologous and allogeneic T cell medications designed to leverage the biology of T cells to…
